Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.
about
Enteroaggregative Escherichia coli: An Emerging Enteric Food Borne PathogenVaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoeaFunctional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell ResponsesClinical implications of enteroadherent Escherichia coliNew Developments in Traveler's DiarrheaEtiology of diarrhea in Bangladeshi infants in the first year of life analyzed using molecular methods.New technologies for influenza vaccines.Heat-labile- and heat-stable-toxoid fusions (LTR₁₉₂G-STaP₁₃F) of human enterotoxigenic Escherichia coli elicit neutralizing antitoxin antibodiesTransient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.Pilot study of whole-blood gamma interferon response to the Vibrio cholerae toxin B subunit and resistance to enterotoxigenic Escherichia coli-associated diarrhea.Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccineTargeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacyLangerhans cells as targets for immunotherapy against skin cancer.Laser vaccine adjuvant for cutaneous immunization.Recent advances in understanding enteric pathogenic Escherichia coli.High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants.Vaccines against enterotoxigenic Escherichia coli.Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathologyExpert review of the evidence base for prevention of travelers' diarrhea.A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phasTherapeutic Transcutaneous Immunization with a Band-Aid Vaccine Resolves Experimental Otitis Media.An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea.CONSORT 2010 statement: extension to randomised pilot and feasibility trialsThe oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.New routes for allergen immunotherapy.Paediatric travel medicine: vaccines and medications.Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook.Vaccine adjuvants: scientific challenges and strategic initiatives.Parenteral Adjuvant Effects of an Enterotoxigenic Escherichia coli Natural Heat-Labile Toxin VariantParticle based vaccine formulations for transcutaneous immunizationHeat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination.Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines.Travellers' diarrhoea - pros and cons of different prophylactic measures.Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.Towards a Chlamydia trachomatis vaccine: how close are we?Targeting skin dendritic cells to improve intradermal vaccination.Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?Adjuvants for human vaccines.Recent progress toward an enterotoxigenic Escherichia coli vaccine.
P2860
Q21328680-6BF3D4FC-791C-4025-A986-156E5FAC6CAFQ24201328-A041ABA9-1059-458C-ABA0-96AC8877F46DQ26777948-BD1B1F3C-91D3-44E7-A6A5-8146E47712D4Q26865925-4B54536A-9CD6-4B04-B7F0-7AFFFBD57F44Q28387036-07C5D30F-4140-4882-AC66-C8F8DA59629BQ30409328-87FBF1DF-C461-42DC-BC98-704CAB60C8A8Q30411859-D8870448-013E-4580-AF40-22F70A7CA807Q30427618-5DC5DF4C-D9F7-4C76-8441-C9DC8D6BC9A1Q33503623-285DC61B-E780-4CE2-900E-ABD24C87107EQ33825679-DAA7DC99-1FC4-4C31-9A56-E6228310EEF3Q33928456-3BC339F9-9730-4ED9-BD12-5A08A82AA9E1Q34009407-B7E6B381-D52A-4A45-9823-69C067C30B40Q34009436-6B3C244A-5C91-409B-BC4F-DDC6A3393832Q34046148-19B19CA0-0246-4955-A2E2-C08676D55FD0Q34375210-36B4C3A7-E4EB-4D1F-AF4C-F6A2A5DE4027Q34466125-0DF365AD-7FB4-485E-AA3F-43107C612B82Q34594874-1782C763-C3A2-4B11-831F-AF997255E9E0Q34685461-CF768534-2001-4EAC-9D6A-DA96E41F72EEQ34987670-37173C02-0C52-41A1-972E-3E83AFD0A9E4Q35598235-C0AB78A4-39E7-4F19-A47B-DE7C0F9C25F9Q35901982-7CA77164-FB33-4026-BEBD-130CB8A8E8BAQ35944776-0C0DC30A-8045-47AA-92C8-768ED889A07EQ35998767-F6E6389A-DC8D-4072-95D1-3F9C200B3399Q36173563-56BAA540-706A-482F-B755-FACB9C0F413CQ36505159-CFD1B90F-DE8F-41FB-A4B2-1C7304C59103Q36864957-B8C01306-E77E-41A7-894A-8E85D49D6C2DQ36948104-ADA7AC57-3546-4DCF-8F49-6E73F215E763Q37316009-E8F3EF8C-FF93-4F55-B111-81F3E72BC00DQ37403484-C9EDA506-7D00-42BD-96D9-F4497874C13BQ37441681-500F3FFE-DE8E-4E8B-BEF5-347B99727C6AQ37530378-779AC8A5-B7E7-4433-8893-6429C290CBA4Q37561165-BF4D0129-162E-4569-A973-40027796F13BQ37593785-5E2664F2-C2BF-48F8-A5E9-0F132485A35CQ37633392-35D31575-37C4-41CA-845C-674A4A657BE7Q37634138-BAFF7328-C579-4731-9D97-831DD6BFDFE3Q37820669-59DC2C7F-1DDF-48BD-84C1-19EEA3E22B49Q37831193-D143F3AC-DC85-4DDB-9841-BB3A057BB77BQ37868794-3DF691BE-E4D8-492F-85A3-A7411FFAE83AQ38004229-BEDEC817-978A-4DC9-A2FA-5B0DF9FFF5D6Q38006998-88692F9C-38D7-42E1-8471-8742E2A4CF51
P2860
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Use of a patch containing heat ...... lacebo-controlled field trial.
@ast
Use of a patch containing heat ...... lacebo-controlled field trial.
@en
Use of a patch containing heat ...... lacebo-controlled field trial.
@nl
type
label
Use of a patch containing heat ...... lacebo-controlled field trial.
@ast
Use of a patch containing heat ...... lacebo-controlled field trial.
@en
Use of a patch containing heat ...... lacebo-controlled field trial.
@nl
prefLabel
Use of a patch containing heat ...... lacebo-controlled field trial.
@ast
Use of a patch containing heat ...... lacebo-controlled field trial.
@en
Use of a patch containing heat ...... lacebo-controlled field trial.
@nl
P2093
P921
P1433
P1476
Use of a patch containing heat ...... placebo-controlled field trial
@en
P2093
A Louis Bourgeois
Ana S Hoffman
Bo H Andersen
Christina P Villar
David C Flyer
Francisco G Martinez-Sandoval
Gregory M Glenn
Herbert L Dupont
Jaime Belkind-Gerson
Jane Halpern
P304
P356
10.1016/S0140-6736(08)60839-9
P407
P577
2008-06-01T00:00:00Z